Lung
RAD204
Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium -177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Solid Tumours.
Trial overview
Clinical Area
Theranostics
Disease
Lung
Disease site
Lung & bronchus
Study Phase
0
Trial Identifiers
Registration number: NCT06305962
GenesisCare Location(s)
Principal Investigator(s)
Clinical trials enquiries